AR118191A1 - MÉTODOS PARA EL TRATAMIENTO DE ENFERMEDADES RELACIONADAS CON TNFa - Google Patents

MÉTODOS PARA EL TRATAMIENTO DE ENFERMEDADES RELACIONADAS CON TNFa

Info

Publication number
AR118191A1
AR118191A1 ARP200100519A ARP200100519A AR118191A1 AR 118191 A1 AR118191 A1 AR 118191A1 AR P200100519 A ARP200100519 A AR P200100519A AR P200100519 A ARP200100519 A AR P200100519A AR 118191 A1 AR118191 A1 AR 118191A1
Authority
AR
Argentina
Prior art keywords
methods
tnf
tnfa
treatment
related diseases
Prior art date
Application number
ARP200100519A
Other languages
English (en)
Inventor
Jin Sun Jung
So Hye Jo
Joon Ho Lee
Sun Hee Lee
Si Young Yang
Jee Hye Suh
Sera Kim
Sun Jung Kim
Original Assignee
Celltrion Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celltrion Inc filed Critical Celltrion Inc
Publication of AR118191A1 publication Critical patent/AR118191A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Abstract

La presente se refiere a métodos para el tratamiento de una enfermedad relacionada con TNF-a mediante la administración subcutánea de un anticuerpo que se une a TNF-a (anticuerpo anti-TNF-a) o fragmento de unión a antígeno del mismo. En comparación con la inyección intravenosa, el método de tratamiento, la composición, el kit o el uso de acuerdo con la presente, ofrece la ventaja de mejorar la satisfacción del paciente, al mejorar su comodidad y calidad de vida, es decir, al reducir el tiempo requerido para la administración y disminuir la estancia del paciente en el hospital.
ARP200100519A 2019-02-28 2020-02-26 MÉTODOS PARA EL TRATAMIENTO DE ENFERMEDADES RELACIONADAS CON TNFa AR118191A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR20190023769 2019-02-28

Publications (1)

Publication Number Publication Date
AR118191A1 true AR118191A1 (es) 2021-09-22

Family

ID=72239651

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP200100519A AR118191A1 (es) 2019-02-28 2020-02-26 MÉTODOS PARA EL TRATAMIENTO DE ENFERMEDADES RELACIONADAS CON TNFa

Country Status (8)

Country Link
US (1) US20220153828A1 (es)
JP (1) JP2022521996A (es)
KR (1) KR20200105439A (es)
AR (1) AR118191A1 (es)
CA (1) CA3130921A1 (es)
TW (1) TW202045137A (es)
UY (1) UY38595A (es)
WO (1) WO2020175954A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20190448A1 (es) 2016-06-30 2019-03-29 Celltrion Inc Formulacion farmaceutica liquida estable

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2385745C (en) * 2001-06-08 2015-02-17 Abbott Laboratories (Bermuda) Ltd. Methods of administering anti-tnf.alpha. antibodies
TWI556829B (zh) * 2004-04-09 2016-11-11 艾伯維生物技術有限責任公司 用於治療ＴＮＦα相關失調症之多重可變劑量療法
US20070041905A1 (en) * 2005-08-19 2007-02-22 Hoffman Rebecca S Method of treating depression using a TNF-alpha antibody
JP6130350B2 (ja) * 2011-03-30 2017-05-17 アブリンクス エン．ヴェー． ＴＮＦαに対する単一ドメイン抗体で免疫障害を処置する方法
KR20190024572A (ko) * 2017-08-30 2019-03-08 (주)셀트리온 TNFα 관련 질환을 치료하기 위한 피하 투여 요법

Also Published As

Publication number Publication date
KR20200105439A (ko) 2020-09-07
TW202045137A (zh) 2020-12-16
WO2020175954A1 (ko) 2020-09-03
UY38595A (es) 2020-09-30
JP2022521996A (ja) 2022-04-13
CA3130921A1 (en) 2020-09-03
US20220153828A1 (en) 2022-05-19

Similar Documents

Publication Publication Date Title
AR110203A1 (es) Anticuerpos anti-tim-3 para combinación con anticuerpos anti-pd-1
AR080564A1 (es) Metodos para el tratamiento o prevencion de enfermedades asociadas al receptor del factor de crecimiento epidermico humano-3 (her-3)
CO2018007582A2 (es) Método para tratar o mejorar trastornos metabólicos con proteínas de unión para el receptor peptídico inhibidor gástrico (gipr) en combinación con agonistas de glp-1
CO6150193A2 (es) Terapia tumoral con anticuerpo anti-vegf
BR112021009856A8 (pt) Terapia para tratamento do câncer com uma administração intratumoral e / ou intravenosa de um mva recombinante que codifica 4-1bbl (cd137l) e / ou cd40l
BRPI0711908B8 (pt) anticorpo anti-interleucina-18 humanizado, composição farmacêutica, uso de um anticorpo anti-interleucina 18, e, método de produção de um anticorpo.
CR20230302A (es) MÉTODO PARA TRATAR O MEJORAR TRASTORNOS METABÓLICOS MEDIANTE EL USO DE AGONISTAS DEL RECEPTOR Glp-1 CONJUGADOS CON ANTAGONISTAS DEL RECEPTOR DEL PÉPTIDO INHIBIDOR GÁSTRICO (GIPR) (Div. 2019-380)
CO6260078A2 (es) Metodo y tratamiento del trastorno por estres postraumatico mediante la administracion de un agente seleccionado entre benzodiazepina, un inhibidor (isrs) y otros
EA201890182A1 (ru) Терапевтическое средство для лечения синдрома гунтера и способ его лечения
CL2022002813A1 (es) Semaglutida para el tratamiento de esteatohepatitis no alcoholica.
AR118191A1 (es) MÉTODOS PARA EL TRATAMIENTO DE ENFERMEDADES RELACIONADAS CON TNFa
PE20200013A1 (es) Metodo para tratar o mejorar trastornos metabolicos con proteinas de union para el receptor peptidico inhibidor gastrico (gipr) en combinacion con agonistas de glp-1
BR112019022912A2 (pt) Métodos e composições para tratar doenças oculares alérgicas
BR112023022264A2 (pt) Esteroide c21-n-pirazolil 19-nor c3,3-dissubstituído e métodos de uso do mesmo
DOP2020000049A (es) MÉTODOS PARA EL TRATAMIENTO DE ENFERMEDADES RELACIONADAS CON TNFa
CL2021000924A1 (es) Uso de reboxetina para el tratamiento de narcolepsia
EA202290027A1 (ru) Способы и композиции для улучшения результатов лечения пациентов с раком
BR112021013096A2 (pt) Tratamento de doença de sjögren com proteínas de fusão de nuclease
EA202190226A1 (ru) СПОСОБЫ ЛЕЧЕНИЯ HFpEF С ИСПОЛЬЗОВАНИЕМ ДАПАГЛИФЛОЗИНА И СОДЕРЖАЩИХ ЕГО КОМПОЗИЦИЙ
CL2023000121A1 (es) Anticuerpos anti-il-36r para el tratamiento de dermatosis neutrófilas
CL2022001984A1 (es) Composiciones métodos para aumentar, mejorar transducción vectores de terapia génica y para eliminar, reducir inmunoglobulinas
AR112535A1 (es) MÉTODOS PARA EL TRATAMIENTO DE ENFERMEDADES RELACIONADAS CON TNFa
AR116897A1 (es) Métodos para tratar el cáncer con una combinación de un anticuerpo anti-vegf y un conjugado anticuerpo-fármaco anti-factor tisular
RU2010141591A (ru) Способ лечения пациентов с острой цереброваскулярной патологией на фоне посттравматического стрессового расстройства, выполняемый комбинированной психомедикаментозной терапией
MX2022003668A (es) Metodos y composiciones para el tratamiento de la retinopatia diabetica.

Legal Events

Date Code Title Description
FB Suspension of granting procedure